Nine innovative projects within health tech, bio-industrials and therapeutics have been awarded the Proof of Concept (PoC) grant by BioInnovation Institute.
The program supports researchers whose next step is to establish their project’s preliminary proof of concept. Throughout the 12 months long program, the researchers will continue the work at their current institution or workplace. Each of them has received close to DKK 1M.
“The applying projects are of very high quality. Amongst the accepted projects are an exciting bio-industrial project on probiotic bacteria for fertilizing plants, and a health tech project on the development of a small wireless device to explore the functions of nerves and muscles. We are excited to see such large interest from all the universities” says Louise Clemmensen, Scientific Developer.
Congratulations to the accepted projects!
Kim Theilgaard-Mönch from the University of Copenhagen for the therapeutics project: Curative low toxicity antibody-drug conjugate therapy for cancer patients.
Anders Bach from the University of Copenhagen for the therapeutics project: Developing novel inhibitors of NADPH oxidase 2 (NOX2), to limit oxidative stress and inflammation in many diseases.
Andreas Lodberg from Aarhus University for the therapeutics project: Novel biological therapeutics using fusion protein approach for development of follistatin (FST) drug candidates for prevention of muscle wasting.
Thomas Poulsen from Aarhus University for the therapeutics project: Development of a small molecule degrader of CYB5B – a nexus of a metabolic pathway involved in liver pathologies.
Grith Lykke Sørensen from the University of Southern Denmark for the therapeutics project: A novel biological therapy for liver fibrosis.
Hanne Ingmer from the University of Copenhagen for the therapeutics project: Aims at developing a new antibiotic acting through inhibition of the protein factories of cells (ribosome).
Ling Ding from the Technical University of Denmark for the bio-industrial project: Plant-growth promoters from soil Actinobacteria.
Jonas Heilskov Graversen from the University of Southern Denmark for the therapeutics project: An antibody-drug conjugate for therapeutic targeting of CD163+ tumor-associated macrophages, preventing recruitment of T-cells to the tumor.
Michael Pedersen from Aarhus University for the health tech project: A precision portable, cheap and wireless electrophysiology examination device for human use for nerve examination in patients.
From Wednesday, July 1st, the PoC grants will be administered by the Novo Nordisk Foundation. Please contact Lene Thorsen on email: email@example.com for additional information.
Read more about BII’s programs here: http://bii.dk/programs